secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001104659-24-062263
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17
--------------------------------------------------------------------------------

- Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.
- Nasdaq ticker symbol changes from FWBI to ENTO at market open on May 17.
- Rebranding follows recent business combination with ImmunogenX, reflecting GI-focused pipeline.
- Lead asset latiglutenase for celiac disease; Phase 3 trial expected to begin early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/0001104659-24-062263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465924062263/tm2414628d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer